In addition, immune checkpoint therapies targeting Tregs, such as CTLA-4 blockade, anti-PD-1 therapy, OX40, and TIGIT, have also been reported to induce myocarditis, skeletal myositis, and colitis in cancer patients, while limiting the clinical application [123]. The gene discussed is TNFRSF4; the disease is cancer.